FASN and ovarian carcinoma: In our study, we aimed to investigate whether the effects of FASN inhibition by orlistat could overcome cisplatin resistance in ovarian cancer by using it in combination with cisplatin in a cisplatin‐refractory ovarian carcinoma xenograft mouse model and validating the tumour response on histopathology.